Table 1a.
Clinical characteristics of the derivation samples
| Analysis stratum | US | UK | |||||
|---|---|---|---|---|---|---|---|
| Subject Source | BWH | WU | ACP | UCSF | RUSH | UC | 1958 BC |
| Number of controls | 4071 | 13 | 35 | 142 | 489 | - | 1030 |
| Number of Cases | 227 | 152 | 597 | 407 | - | 831 | - |
| Female: Male ratio | 2.8:1.0 | 3.1:1.0 | 3.1:1.0 | 5.6:1.0 | - | 2.28:1.0 | - |
| Mean Disease Duration, years (range) | 12 (<1–58) | 13 (<1–39) | 15 (1–56) | 12(<1–47) | - | 14 (<1–54) | - |
| Mean age at onset, years (range) | 33 (8–59) | 33 (13–71) | 33 (1–70) | 42 (3–60) | - | 32 (10–67) | - |
|
| |||||||
|
Disease course, n (%)
|
- | - | |||||
| “Bout onset” | 178 (78%) | 128 (84%) | 463 (78%) | 345 (85%) | - | 732 (88%) | - |
| Relapse Remitting | 136 (60%) | 106 (70%) | 358 (60%) | 237 (58%) | - | NA2 | - |
| Secondary Progressive | 42 (19%) | 22 (14%) | 105 (18%) | 111 (27%) | - | NA2 | - |
| Primary Progressive | 17 (8%) | 17 (11%) | 36 (6%) | 23 (6%) | - | 84 (10%) | - |
| Clinically Isolated Syndrome | 25 (11%) | 7 (4%) | 75 (13%) | 10 (2%) | - | 0 (0%) | - |
| Unknown | 7 (3%) | 0 | 23 (4%) | 26 (6%) | - | 15 (2%) | - |
BWH controls – these subjects of European ancestry recruited in the Boston area include (1) unaffected spouses from our MS Genetics collections (n=14), (2) The BWH PhenoGenetic Project subjects (n=292), and healthy subjects from the HPCGG collection (n=101) (see methods for details). These subjects do not overlap with BWH control subjects used in the meta-analysis.
NA – the breakdown of remitting relapsing and secondary progressive subjects is not available in this cohort.
Glossary: 1958 BC – 1958 birth cohort; ACP – Accelerated Cure Project; BWH – Brigham & Women’s Hospital; RUSH – RUSH University; UC – University of Cambridge, UK; UCSF – University California, San Francisco; UK – United Kingdom; US – United States; WU – Washington University, St. Louis